{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:41Z","timestamp":1794003881895,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijgc.2026.104852","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:05:35Z","timestamp":1783091135000},"page":"104852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal kinetics of human epididymis protein 4 in recurrent advanced ovarian carcinoma treated with platinum-based chemotherapy: mathematical modeling and prognostic implications"],"prefix":"10.1016","volume":"36","author":[{"given":"Petra","family":"Nardelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Leitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8835-2865","authenticated-orcid":false,"given":"Aurore","family":"Carrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Irsara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Jaritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Triendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5213-6237","authenticated-orcid":false,"given":"Simon","family":"Schnaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-2562","authenticated-orcid":false,"given":"Pauline","family":"Corbaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-9981","authenticated-orcid":false,"given":"Christian","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1236-6806","authenticated-orcid":false,"given":"Heidelinde","family":"Fiegl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-8857","authenticated-orcid":false,"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-3470","authenticated-orcid":false,"given":"Olivier","family":"Colomban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.104852_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104852_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104852_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1200\/JCO.22.00430","article-title":"CA-125 KELIM as a potential complementary tool for predicting veliparib benefit: an exploratory analysis from the VELIA\/GOG-3005 study","volume":"41","author":"You","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104852_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-022-01732-7","article-title":"Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era","volume":"127","author":"You","year":"2022","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104852_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.106032","article-title":"ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer","volume":"11","author":"Gonz\u00e1lez-Mart\u00edn","year":"2026","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104852_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104852_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41416-023-02528-z","article-title":"Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer","volume":"130","author":"Zebic","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104852_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112966","article-title":"Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: a Gynaecologic Cancer Intergroup meta-analysis","volume":"191","author":"Corbaux","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2026.104852_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102294","article-title":"The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas","volume":"100","author":"You","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104852_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/cancers14010098","article-title":"The increasing prognostic and predictive roles of the tumor primary chemosensitivity assessed by CA-125 elimination rate constant K (KELIM) in ovarian cancer: a narrative review","volume":"14","author":"Lauby","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104852_bib11","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104852_bib12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/diagnostics13030452","article-title":"Evaluation of He4 use in the diagnosis of ovarian cancer: first and second recurrence, and an analysis of HE4 concentration during second- and third-line chemotherapy","volume":"13","author":"Chudecka-G\u0142az","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ijgc.2026.104852_bib13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fonc.2018.00124","article-title":"Beyond the biomarker: understanding the diverse roles of human epididymis Protein 4 in the pathogenesis of epithelial ovarian cancer","volume":"8","author":"James","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijgc.2026.104852_bib14","series-title":"Longitudinal Kinetics of HE4 in First-Line Treatment of Advanced Ovarian Carcinoma: Mathematical Modeling and Prognostic Implications","author":"Leitner","year":"2025"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104852_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-020-04086-0","article-title":"Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate","volume":"86","author":"Dekeister","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijgc.2026.104852_bib16","article-title":"Prognostic value of the modeled prostate-specific antigen KELIM confirmation in metastatic castration-resistant prostate cancer treated with taxanes in FIRSTANA","volume":"8","author":"Carrot","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104852_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13148-024-01781-0","article-title":"BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer","volume":"16","author":"Fiegl","year":"2024","journal-title":"Clin Epigenetics"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104852_bib18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/cancers16112129","article-title":"Stratification of homologous recombination deficiency-negative high-grade ovarian cancer by the type of peritoneal spread into two groups with distinct survival outcomes","volume":"16","author":"Schnaiter","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104852_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: A comparison with prostate-specific antigen across five randomized Phase III clinical trials","volume":"36","author":"Heller","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104852_bib20","series-title":"NONMEM User\u2019s guides (1989-2009)","author":"Beal","year":"2009"},{"key":"10.1016\/j.ijgc.2026.104852_bib21","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104852_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2018.08.025","article-title":"A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index","volume":"151","author":"Lycke","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104852_bib23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2012.07.106","article-title":"Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass","volume":"127","author":"Karlsen","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104852_bib24","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1007\/s13277-015-4031-9","article-title":"The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study","volume":"37","author":"Nassir","year":"2016","journal-title":"Tumour Biol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104852_bib25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4 have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"Plotti","year":"2012","journal-title":"Tumour Biol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104852_bib26","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1007\/s13277-014-1836-x","article-title":"Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104852_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104852_bib28","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3892\/or.2013.2682","article-title":"Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer","volume":"30","author":"Manganaro","year":"2013","journal-title":"Oncol Rep."},{"issue":"8","key":"10.1016\/j.ijgc.2026.104852_bib29","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/IGC.0000000000000218","article-title":"The role of HE4 in ovarian cancer follow-up: a review","volume":"24","author":"Piovano","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104852_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nm.2989","article-title":"Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis","volume":"19","author":"LeBleu","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104852_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/labmed\/lmx036","article-title":"Human epididymis Protein 4 as a potential biomarker of chronic kidney disease in female patients with normal ovarian function","volume":"48","author":"Yuan","year":"2017","journal-title":"Lab Med"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104852_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ygyno.2021.01.011","article-title":"Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES)","volume":"161","author":"Cramer","year":"2021","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2600383X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2600383X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:31:34Z","timestamp":1794000694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2600383X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1048891X2600383X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104852","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal kinetics of human epididymis protein 4 in recurrent advanced ovarian carcinoma treated with platinum-based chemotherapy: mathematical modeling and prognostic implications","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104852"}}